Highthroughput Screening Core

高通量筛选核心

• 批准号: 8459889
• 负责人: M CARRIE MICELI
• 金额: $ 18.99万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-04-01 至 2014-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8459889
• 关键词: Address; Adoption; Biological Assay; Cell Culture Techniques; Cell model; Cells; Chemicals; Clinic; Clinical Trials; Development; Fibroblasts; Goals; Human Resources; Image; Investments; Lead; Muscle; Muscle Cells; Muscular Dystrophies; Myopathy; Pharmaceutical Preparations; Proteins; Reagent; Research Personnel; Resources; Robotics; Services; Small Interfering RNA; Staging; Technical Expertise; Technology; Testing; Therapeutic; Validation; assay development; cDNA Library; data mining; design; drug discovery; high throughput screening; novel strategies; novel therapeutics; screening; skills; therapeutic development; tool; translational medicine; trend

Recent progress in elucidating the mechanisms underlying muscular dystrophy and muscle disease has dramatically increased the number of protein targets available for potential drug treatment. Concurrently, new approaches have increased the number of compounds that can be tested for activity against these targets. Together, these trends have stimulated the adoption of high-throughput screening (HTS) as a primary tool for early-stage drug discovery. While HTS has only been applied to a limited set of muscular dystrophy targets, early application of this approach has already lead to the development of therapeutics currently being tested in the clinic. This has lead to increased enthusiasm worldwide and among UCLA MDTRaC Investigators for designing and implementing muscular dystrophy relevant assays for drug discovery. UCLA has already made a tremendous commitment to HTS screening on campus in the form of the UCLA MSSR as one mechanism by which to facilitate translational medicine, in general. However, access to this resource is currently limited by available manpower, cell models, expertise and space for cell expansion and handling of muscle lineage and muscular dystrophy relevant cells. To address this limitation we propose to create a muscle relevant HTS Core that will utilize the robotics and imaging capabilities of the MSSR and will provide manpower, expertise, space, resources, and guidance on muscle cell and fibroblast culture. In this context the HTS Assay Core will: Aim 1) advise users in assay development and provide access to available muscle and muscular dystrophy relevant cell models; Aim 2) provide cell culture expansion and plating (in HTS format) and MSSR interfacing services, Aim 3) retrieve and analyze and mine data collected at the MSSR; and Aim 4) aid in development and implementation of secondary assays for lead hit compound validation. Thus, the proposed core maximizes impact by leveraging the existing tremendous investment in HTS technology already available on campus and implementing the needed resources and skills to

阐明肌肉营养不良和肌肉疾病的机制的最新进展已有 大大增加了可用于潜在药物治疗的蛋白质靶标数量。同时 新方法增加了可以针对这些活动测试的化合物的数量 目标。总之，这些趋势刺激了高通量筛查（HTS）作为一个 早期药物发现的主要工具。虽然HTS仅应用于有限的肌肉 营养不良靶点，这种方法的早期应用已经导致治疗剂的发展 目前正在诊所进行测试。这导致了全球和加州大学洛杉矶分校之间的热情 MDTRAC研究人员设计和实施肌营养不良的药物相关测定法 发现。加州大学洛杉矶分校已经对HTS在校园中的放映做出了巨大承诺。 一般而言，UCLA MSSR是一种促进转化医学的一种机制。然而， 目前，该资源的访问受可用的人力，单元模型，专业知识和小组空间的限制 肌肉谱系和肌肉营养不良相关细胞的扩展和处理。解决这个限制 我们建议创建一个相关的HTS核心，该核心将利用机器人技术和成像功能 MSSR并将提供有关肌肉细胞的人力，专业知识，空间，资源和指导 成纤维细胞培养。在这种情况下 提供可用的肌肉和肌肉营养不良相关的细胞模型；目标2）提供单元格 培养扩展和电镀（以HTS格式）和MSSR接口服务，目标3）检索和分析 和在MSSR收集的矿山数据；目标4）协助开发和实施次要 铅命中复合验证的测定。因此，提出的核心通过利用 现有的对HTS技术的巨额投资已经在校园内提供并实施 需要资源和技能